Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases.

Oral semaglutide in kidney transplant recipients with metabolic syndrom - Oral semaglutide in kidney transplant recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050853

Enrollment

Registered

2023-04-15

Start date

2021-12-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplant recipients with metabolic syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Post renal transplant recipient with metabolic syndrome complications

Exclusion criteria

Exclusion criteria: Insulin user

Design outcomes

Primary

Measure	Time frame
Change in body weight after 12 months of oral semaglutide administration	—

Secondary

Measure	Time frame
Change in eGFR 12 months after initiation of oral semaglutide	—

Countries

Japan

Contacts

Public ContactRYOICHI MIYAZAKI

Fujita Memorial Hospital Internal Medicine

ryoichi@mitene.or.jp+81-776-21-1277

Outcome results